[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-217216-en":3,"doc-seo-217216-105":29,"detail-sidebar-cat-0-en-105":93},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":4,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":20,"language":21,"language_code":22,"site_id":23,"html_lang":22,"table_of_contents":24,"faqs":25,"seo_title":26,"seo_description":14,"update_tm":27,"read_time":28},217216,13056703019404,"Miles","https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0",8,"Research & Report","Smoldering Multiple Myeloma in Latin America - Risk Stratification - Poster 3774","Smoldering multiple myeloma (SMM) is characterized by limited regional evidence in Latin America. This study aims to describe SMM features across the LA region and to assess validity of the 2-20-20 SMM risk stratification. A retrospective cohort enrolled SMM diagnoses from 2015–2023 within a consortium of Brazilian and Latin American myeloma groups, collecting demographics, diagnostic and prognostic tools, progression outcomes, and calculating progression-free and overall survival.","| \u003Cbr>\u003Cbr>\u003Cbr>INTRODUCTION\u003Cbr>• Smoldering multiple myeloma (SMM) has a prevalence of 0 .5% in the >40 yrs population 1\u003Cbr>• SMM represents 4% of the monoclonal gammopathies cases2\u003Cbr>• African-American patients have a lower rate of progression than white 3\u003Cbr>• Latin America represents 64% of America's population,\u003Cbr>• There is scarce data about SMM in LA.\u003Cbr>\u003Cbr>\u003Cbr>AIM\u003Cbr>• To characterize SMM in the LA region.\u003Cbr>• To validate the 2-20-20 SMM risk stratification in LA region.\u003Cbr>\u003Cbr>\u003Cbr>METHODS\u003Cbr>• A consortium between the Brazilian and Latin America myeloma study groups (GBRAM and GELAMM) were stablished to conduct a retrospective cohort study\u003Cbr>• SMM cases diagnosed from 2015 to 2023 were included.\u003Cbr>• Data collected included demographics, diagnostic and prognostic tools.\u003Cbr>• Data of progression to MM and SMM management.\u003Cbr>• Progression-free survival (PFS) and overall survival (OS) were calculated. | \u003Cbr>Smoldering Multiple Myeloma in Latin America-Risk Stratification\u003Cbr>E.Q. Crusoé 1 , A.V. Glasenapp2 , G Ribeiro 3 , L. Perobelli4 , P. Ochoa 5 , F.V. Pericole 6 , S. Lopresti 7 , J. Schmidt 8 , C. Samanez9 , G. Remaggi 10 , E. G. Souza 11 , E. Riva 12 , J. Pineda 13 , P. M. M Garibaldi 14 , M.A. F. Aranha 15 , R. Magalhães 16 , A.G. R. Alvarado 17 , D. Fantl 18 , K. Gálvez 19 , D. Laks20 , J. R. E. Zamora21 , J.S. Lima22 , R. Vallejo23 , A. Hallack24 , F. Stella25 , E. Babuin 5 , G. Virginia26 , H. López-Vidal27 , J. Vasquez 28 , M. E. Enciso29 , R. M. Bustillo 30 , S. P. Roa 31 , C. Peña 32 and V. Hungria 33 on behalf of GELAMM and GBRAM groups\u003Cbr>1 Oncologia D'Or-BA- Brazil, 2- Hospital Central IPS- Paraguay, 3- Clinica Hematológica- Brazil, 4-Hospital de Transplantes Euryclides de Jesus Zerbini- Brazil, 5-Instituto Alexander Fleming- Argentina,6- Hemocentro UNICAMP- Brazil, 7- Hospital Nacional Alejandro Posadas-Argentina, 8-ACCamargo Cancer Center- Brazil,9-AUNA-Peru, 10-FUNDALEU-Argentina, 11-Hospital de Clinicas da UFMG-Brazil, 12-Hospital de Clinicas-Uruguay, 13-Clínica Alemana de Santiago- Chile, 14-Hospital das Clínicas de Ribeirão Preto-USP-Brazil, 15-Hemomed-Brazil, 16-Hospital Universitário UFRJ-Brazil, 17-Centro Medico Nacional la Raza- Mexico , 18-Hospital Italiano de Buenos Aires- Argentina, 19-Pablo Tobón Uribe-Colombia, 20-Hospital Moinhos de Vento-Brazil, 21- Instituto Nacional de Cancerologia-México, 22-Oncoclínicas Curitiba- Brazil, 23-Hospital Español de Buenos AiresArgentina,, 24-Hospital Universitario Universidade Federal de Juiz de Fora- Brasil, 25-Hospital Nacional Alejandro Posadas/Universidad de Moron-Argentina, 26-San Martin de Parana-Argentiva, 27-Clínica Dávila-Chile, 28-INEM-Peru, 29-Instituto de Prevision Social-Praguay, 30-Sanatorio Allende-Argentina, 31-Bradford Hill-Chile, 32-Hospital del Salvador-Chile, 33-Clínica São Germano-SP-Brazil |  |\n| --- | --- | --- |\n|  | \u003Cbr>\u003Cbr>RESULTS\u003Cbr>Table 1-Demographics and baseline patients characteristics\u003Cbr>N=260 Median age at diagnosis (range) 63 (33-90) Gender n (%) Female 166 (63.8) Male 94 (36.2) Ig Isotype n (%) IgG 167 (64.2) IgA 74 (28.4) FLC 17 (6.5) IgG/IgA 1 (0.4) Negative 1 (0.4) Institution origin n (%) Private 164 (63.1) Public 96 (36.9) FISH study n(%) Yes 95 (36.5) No 163 (62.7) NA 2 (0.8) SMM treatment n(%) Yes 21 (8.1) No 238 (91.5) NA 1 (0.4)\u003Cbr>FLC-Free light chain; FISH-Fluorescent in situ hybridization; NA-Not available\u003Cbr>Table 2-Patients by country distribution\u003Cbr>n (%) N=260 Brasil 147 (56.6) Argentina 55 (21.2) Chile 22 (8.5) Peru 10 (3.8) Paraguay 9 (3.5) México 7 (2.7) Uruguay 6 (2.3) Colombia 4 (1.5)\u003Cbr>Table 3-Imaging accessibility profile\u003Cbr>n (%) WBLDCT Yes\u003Cbr>No 110 (42.5)\u003Cbr>149 (57.5) PET-CT Yes 124 (47.9) No 135 (52.1) WBMRI Yes 105 (40.5) No 154 (59.5)\u003Cbr>WBLDCT-Whole body low density computerized tomography;PET-positron emission tomography; WBMRI-whole body magnetic resonance,\u003Cbr>\u003Cbr>Table 4-Treatment, risk and progression from SMM status\u003Cbr>N=21 (8.1%) 20-2-20 Risk Myeloma Progression 1 VRd High No 2 CyBor","cbCaik89fLUXPfct","https://ap.wps.com/l/cbCaik89fLUXPfct","pdf",327634,1,"English","en",105,"# Introduction\n# Aim\n# Methods\n# Results\n## Table 1\n## Table 2\n## Table 3\n## Table 4\n## Figure 1\n# Conclusions\n# References\n# Acknowledgements\n# Contact Information","[{\"question\":\"What is the main purpose of the study on smoldering multiple myeloma in Latin America?\",\"answer\":\"The study characterizes SMM in the Latin America region and validates the 2-20-20 SMM risk stratification for that population.\"},{\"question\":\"How was the study conducted and who was included?\",\"answer\":\"A retrospective cohort consortium from Brazilian and Latin America myeloma study groups included SMM cases diagnosed from 2015 to 2023, with data collected on demographics and diagnostic/prognostic tools.\"},{\"question\":\"Which outcomes were calculated to evaluate risk and progression?\",\"answer\":\"Progression-free survival (PFS) and overall survival (OS) were calculated, and progression timing was assessed according to the 2-20-20 risk criteria.\"},{\"question\":\"What were the key conclusions about regional access and risk criteria?\",\"answer\":\"The work reports exclusive Latin American representation, highlights limited public-sector surveillance for SMM diagnosis tools, and demonstrates that the 2-20-20 criteria impact progression in the study population.\"}]","Smoldering Multiple Myeloma in Latin America - Risk Stratification - Poster 3774 | PDF",1788831522,3,{"code":4,"msg":30,"data":31},"ok",{"site_id":23,"language":22,"slug":32,"title":13,"keywords":33,"description":14,"schema_data":34,"social_meta":88,"head_meta":90,"extra_data":92,"updated_unix":27},"smoldering-multiple-myeloma-in-latin-america-risk-stratification-poster-3774","",{"@graph":35,"@context":87},[36,52,66],{"@type":37,"itemListElement":38},"BreadcrumbList",[39,43,47,49],{"item":40,"name":41,"@type":42,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":44,"name":45,"@type":42,"position":46},"https://docshare.wps.com/document/","Document",2,{"item":48,"name":12,"@type":42,"position":28},"https://docshare.wps.com/document/research-report/",{"item":50,"name":13,"@type":42,"position":51},"https://docshare.wps.com/document/smoldering-multiple-myeloma-in-latin-america-risk-stratification-poster-3774/217216/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"inLanguage":22,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":40,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-09-08",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79,83],{"name":70,"@type":71,"acceptedAnswer":72},"What is the main purpose of the study on smoldering multiple myeloma in Latin America?","Question",{"text":73,"@type":74},"The study characterizes SMM in the Latin America region and validates the 2-20-20 SMM risk stratification for that population.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"How was the study conducted and who was included?",{"text":78,"@type":74},"A retrospective cohort consortium from Brazilian and Latin America myeloma study groups included SMM cases diagnosed from 2015 to 2023, with data collected on demographics and diagnostic/prognostic tools.",{"name":80,"@type":71,"acceptedAnswer":81},"Which outcomes were calculated to evaluate risk and progression?",{"text":82,"@type":74},"Progression-free survival (PFS) and overall survival (OS) were calculated, and progression timing was assessed according to the 2-20-20 risk criteria.",{"name":84,"@type":71,"acceptedAnswer":85},"What were the key conclusions about regional access and risk criteria?",{"text":86,"@type":74},"The work reports exclusive Latin American representation, highlights limited public-sector surveillance for SMM diagnosis tools, and demonstrates that the 2-20-20 criteria impact progression in the study population.","https://schema.org",{"og:url":50,"og:type":89,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":91,"canonical":50},"index,follow",{"doc_id":7,"site_id":23},{"code":4,"msg":5,"data":94},[95,99,103,107,112,117,122,125,130,133,137],{"id":20,"doc_module":4,"doc_module_name":45,"category_name":96,"show_sort_weight":97,"slug":98},"Story & Novel",90,"story-novel",{"id":46,"doc_module":4,"doc_module_name":45,"category_name":100,"show_sort_weight":101,"slug":102},"Literature",80,"literature",{"id":51,"doc_module":4,"doc_module_name":45,"category_name":104,"show_sort_weight":105,"slug":106},"Exam",70,"exam",{"id":108,"doc_module":4,"doc_module_name":45,"category_name":109,"show_sort_weight":110,"slug":111},5,"Comic",60,"comic",{"id":113,"doc_module":4,"doc_module_name":45,"category_name":114,"show_sort_weight":115,"slug":116},6,"Technology",50,"technology",{"id":118,"doc_module":4,"doc_module_name":45,"category_name":119,"show_sort_weight":120,"slug":121},7,"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":45,"category_name":12,"show_sort_weight":123,"slug":124},30,"research-report",{"id":126,"doc_module":4,"doc_module_name":45,"category_name":127,"show_sort_weight":128,"slug":129},9,"Religion & Spirituality",20,"religion-spirituality",{"id":128,"doc_module":4,"doc_module_name":45,"category_name":131,"show_sort_weight":128,"slug":132},"World Cup","world-cup",{"id":134,"doc_module":4,"doc_module_name":45,"category_name":135,"show_sort_weight":134,"slug":136},10,"Lifestyle","lifestyle",{"id":138,"doc_module":4,"doc_module_name":45,"category_name":139,"show_sort_weight":108,"slug":140},19,"General","general"]